

### НП АК «ПАМ»

249030, Киевское ш., д.3, г. Обнинск, Калужская обл., Россия  
Для переписки: 249031, а/я 1024, г. Обнинск, Калужская обл., Россия  
Тел.: (484) 399-72-58, факс: (484) 396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

### NP AC PAM

249030, Kievskoye sh., 3, Obninsk, Kaluga region, Russia  
For letters: 249031, P.O.Box 1024, Obninsk, Kaluga region, Russia  
Tel: (484)399-72-58, fax: (484)396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

Dear colleagues,

In this New Year's Digest we would like to share our results of the departing 2015. This year has been productive in clinical research. We have obtained permission and started the phase II clinical trial for two of our experimental drugs: PAM-9 "A Novel Radio- and Chemoprotector, Adjuvant of Radio- and Chemotherapy".

The phase I clinical trial of PAM-1 "A Novel Compound with Antiviral Activity Against Influenza and Other Acute Respiratory Infection Viruses" has been completed. In 2016 we are planning to optimize PAM-1's final dosage form and investigate it in order to improve the pharmacokinetic parameters.

A huge work has been done within the project PAM-3 "Oxygen Carrier". Our efforts ended with receiving the permission to conduct phase I clinical study, which is planned for the beginning of 2016.

Project PAM-14 "An Anticancer Compound" has successfully undergone thorough examinations of the Ministry of Education and Science of the Russian Federation and the Skolkovo Innovation Center.

First-in-human clinical trial is planned for the project PAM-38 "Mild Cognitive Disorder Treatment Drug".

Preclinical studies of an original target-oriented compound for the treatment of cognitive disorders and dementias (PAM-43) continue. Skolkovo's support in 2016 is expected and will be highly appreciated.

A lot has been done within the project "Card Info" – express-tests for early detection of myocardial infarction (LLC "OFC-Cardio"). During 2015 the company "OFC-Cardio" participated in a pilot project that aimed at introducing the diagnostic tests for the early detection of myocardial infarction into the operations of healthcare facilities. The pilot project was implemented in the Kaluga Region. The equipment supply for antibodies conjugation production site and monoclonal antibodies production has successfully completed in July 2015. These sites hosted a grand opening in September. With the opening of the high-tech areas, "OFC-Cardio" has become one of the few Russian companies with a full cycle of development and production of express-test systems with its own production of raw materials (antibodies). This is an example of practical implementation of the Import Substitution Program and opens up opportunities for the development of new diagnostic tests.



A new test system "Cardio-Plus" became the winner of the Quality of Life 2.0 competition held by the Cluster of Biomedical Technologies of the Skolkovo Innovation Center with the support of the Timchenko Foundation. "Cardio-plus" is a two component multiplex immunochromatographic test system for diagnosis of acute myocardial infarction (AMI) within the period of 1 to 72 hours from the symptoms onset. The test system is based on the identification of two cardiac markers of AMI: an early one - cardiac fatty acid binding protein (cFABP) and a late one - Troponin I (TnI).

The Alliance of Competencies "Park of Active Molecules" hosted a grand opening of the Regional Engineering Center (REC) in August 2015. REC is a unified infrastructure area, equipped with modern analytical, laboratory and technological equipment of more than 130 million rubles. REC was created through public-private partnerships for rendering engineering and technological services for small and medium sized biopharmaceutical enterprises of the region. The Alliance has provided space for REC, as well as the competences of qualified professionals required for effective use of the equipment.

In February, the Alliance of Competencies "Park of Active Molecules" and the Cluster of Biomedical Technologies of the Skolkovo Innovation Center concluded a Cooperation Agreement. In November PAM became an official partner of Skolkovo. Three project companies of PAM ("Ciklomemorin" Ltd., "Tiatsen" Ltd. and "Cardio-plus" Ltd.) received the status of Skolkovo residents.



**НП АК «ПАМ»**

249030, Киевское ш., д.3, г. Обнинск, Калужская обл., Россия  
Для переписки: 249031, а/я 1024, г. Обнинск, Калужская обл., Россия  
Тел.: (484) 399-72-58, факс: (484) 396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

**NP AC PAM**

249030, Kievskoye sh., 3, Obninsk, Kaluga region, Russia  
For letters: 249031, P.O.Box 1024, Obninsk, Kaluga region, Russia  
Tel: (484)399-72-58, fax: (484)396-58-79  
E-mail: office@pam-alliance.ru, www.pam-alliance.ru

In May 2015 PAM has become a key Russian partner of international innovative biopharmaceutical company "AstraZeneca" in the framework of the "Open Innovation".

In 2015 a cooperation agreement with PJSC "Moscow Exchange" was signed.

In April four projects of young scientists from PAM have won the contest "UMNIK 2015". In November a project of Kaluga State University student guided by PAM's researcher became the winner of the fall tour of the competition.

During this year the protection of intellectual property was actively performed: 4 patents were received (3 Eurasian and 1 Russian), and 9 applications were filed (4 Russian, 1 international and 4 foreign applications). Moreover, positive decisions were obtained for two patent requests.

Summing up the results of the outgoing 2015, we can say that it was a successful year for us. We are entering the New 2016 with excellent results and a good mood!

It is our pleasure to wish you and your colleagues a magical New Year! Let the coming year bring you good health, prosperity and lots of love. We hope that 2016 will be the year of mutually beneficial cooperation with the Alliance of Competencies "Park of Active Molecules".

HAPPY NEW YEAR!

Yours sincerely,

Rahimdzhан Roziev,

Director of the NP AC "PAM"